Inspections conducted across 49 entities including pharmacies, wholesalers, and clinics to detect violations and misleading marketing practices.
Biocon aims to become the world's leading insulin company, capitalising on larger pharmaceutical rivals' strategic shift towards newer, high-margin GLP-1 diabetes therapies. The company plans to expand its insulin presence across 80 markets, focusing on value maximisation and addressing the indispensable need for insulin, particularly for Type-1 and late-stage Type-2 diabetics.
A new study suggests that newer oral weight loss drugs may do more than suppress appetite, potentially altering brain circuits that control motivation and reward, impacting how one experiences pleasure.
'The innovators have been able to more or less stay where they are, in terms of revenue even as the generics are seeing exponential growth due to their affordability.'
The fast-growing GLP-1 market, propelled by lower-cost generics following patent expiry, is widening availability beyond patients with obesity and diabetes -- but also driving unsupervised, appearance-led demand, according to doctors.
Biocon is actively seeking in-licensing opportunities to expand its biosimilars portfolio, focusing on products that complement existing therapy areas, as the company shifts to a 'consolidate' phase with a strong emphasis on improving capacity utilisation, expanding margins, and driving return on capital employed.
PCOS is being renamed PMOS. Dr Anagha Menon breaks down why the one alphabet change matters and how it affects the diagnosis of this condition for so many women.
'Any promotional activity carried out under the pretext of disease awareness, influencer engagement, corporate campaigns, or similar activities that create brand recall/product visibility of the prescription shall also be treated as violations.'
While the introduction of branded generics is likely to accelerate volumes for GLP-1 agonists, value growth may moderate because of price erosion.
'Weight loss drugs can be life changing but are not without risks,' says Dr Vishnu Radhakrishnan as he explains the truth behind Ozempic and Mounjaro.
'It is not just the US and European opportunity, but it is a huge global opportunity.'
Novak Djokovic suggested that Serena Williams could see Wimbledon as the ideal venue to return to tennis.
Biocon Limited has launched its GLP-1 peptide, liraglutide, for the treatment of diabetes and obesity in the Netherlands, as the biopharmaceutical firm positions itself as a global player in the fast-growing diabetes and obesity market currently dominated by the likes of Novo Nordisk and Eli Lilly.
A strong third-quarter (October-December/Q3) performance for 2025-26 (FY26) has helped the stock of India's largest listed pharmaceutical (pharma) company, Sun Pharmaceutical Industries, gain about 7 per cent since the start of February.
Abbott will exclusively distribute and market Extensior in the country, becoming the second company to secure sole distribution rights for Novo's semaglutide portfolio in India, after Emcure Pharma.
'As more patients are prescribed these drugs, intolerance due to gastrointestinal and other side effects will become more visible, leading to higher discontinuation rates.'
Emcure Pharmaceuticals on Monday said it saw Poviztra, its newly launched semaglutide brand, as a "long-term" opportunity in India's fast-evolving obesity and cardiometabolic therapy market, even as price competition in the glucagon-like peptide-1 (GLP-1) segment intensified.
Most first-time investors may be better served by diversified options such as flexicap or multi-cap funds, which already hold pharma and healthcare stocks.
The 23-time Grand Slam champion, who retired from professional tennis in 2022, will headline a multi-year national marketing campaign for GLP-1 drugs, a company spokesperson said.
The semaglutide patent expiry next year could unleash a wave of generic versions from Indian drugmakers, with prices expected to go lower -- at least 80 per cent.
Prices for Indian consumers are expected to come down significantly from the current Rs 17,000-Rs 26,000 monthly.
After two years of strong gains, smallcap stocks fell sharply in 2025, but the correction may be setting up opportunities for long-term investors.
This innovation works by stimulating our natural organs so that it can produce and maintain the insulin balance.
Indian drugmakers Eris Lifesciences, Wockhardt and Lupin are prepping to cash in when Danish company Novo Nordisk bows out of the human insulin pen market by the end of this year and creates an opportunity estimated to be worth Rs 600-800 crore in the domestic market. Some self-use disposable pens are pre-filled with insulin and others can be reused with new cartridges.
'We recently launched Yesintek in the immunology space.'
Mounjaro is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition.
Blood pressure management is no longer just about a number on a chart
'Obesity is a raging conversation globally now, and manufacturing of generics will pick up after the patent expires.'
Study suggested that constant use of Semaglutide may be linked to development of a condition called non-arteritic ischemic optic neuropathy.
After registering a net profit of Rs 25.1 crore in Q3FY25 and consolidated revenues growing by 7 per cent on a like-for-like basis, Siddharth Mittal, chief executive officer (CEO) and managing director, Biocon, told Sohini Das/Business Standard in a virtual interaction that local manufacturing in the US is a trade off between cost and qualifying to do business there.
Pharma major Dr Reddy's Laboratories delivered a muted operational performance in the fourth quarter of financial year 2024-25 (Q4FY25), even as revenue growth remained healthy. Lower gross margin performance and muted domestic growth are key concerns. Most brokerages have a "Sell" or "Reduce" rating as there are uncertainties related to the development of a new product portfolio and the launch timelines.
India's healthcare and pharmaceutical sectors raised Rs 14,811 crore through initial public offerings (IPOs) in 2024, the largest since 2019, driven by strong domestic demand amid expanding global opportunities. According to data, key contributors to the record fundraising included Sai Life Sciences (Rs 3,043 crore), IKS Health (Rs 2,498 crore), and Sagility India (Rs 2,107 crore).
'However, we have seen weakness in our active pharmaceutical ingredients business.'
Gland Pharma beat muted expectations for Q2FY25. There was increased Ebitda (Earnings before interest, taxes, depreciation and amortisation) loss at Cenexi, the CRAM subsidiary. However, overall Ebitda margin was better than expectations at 21.1 per cent. But given two years of earnings decline in FY23 and FY24, the business may have bottomed and upper-teens EPS (earnings per share) growth looks possible over next two financial years.
'API prices are dragging down margins and impacting our competitive ability.'
Sun Pharmaceutical Industries (Sun Pharma) reported a turnaround in the January-March quarter of the 2022-23 financial year (Q4FY23), declaring a profit after tax (PAT) of Rs 1,984 crore versus a loss of Rs 2,277 crore in Q4FY22. However, that loss in FY22 was due to several exceptional one-time items -- with Rs 3,723.15 crore allocated to settlement of lawsuits in the US and other Exceptional Items adding up to Rs 3,935.75 crore. Adjusted for exceptional items, PAT in Q4FY22 amounts to Rs 2,155 crore, which is a year-on-year (YoY) growth of about 36 per cent.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances